Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse Tumortherapie
Currently, there is no standard systemic treatment for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue. Both rituximab and cladribine have shown some activity in this disease, but the combination has not been tested so far. In view of this, we initiated a phase II s...
שמור ב:
| Principais autores: | , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Ferrata Storti Foundation
2013-02-01
|
| סדרה: | Haematologica |
| גישה מקוונת: | https://haematologica.org/article/view/6563 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|